About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Stroke is a medical emergency and one of the leading causes of death and disability worldwide. In this context, the Neurovascular Diseases Group was established in 2001, focusing on biomedical research into both ischemic and hemorrhagic stroke from a basic and translational perspective. Our work in this research field has covered the entire disease spectrum, from prevention and treatment to recovery. In 2017, we expanded our research interests to include vascular dementia and Alzheimer’s disease, related to the β-amyloid protein. Our ultimate goal as a research team is to help answer critical questions that will improve the clinical management of stroke and dementia, conditions with significant health impacts due to their high prevalence and associated disability. We are also committed to promoting scientific education among researchers and the society, and to fostering public engagement in these areas.
Since 2001, dozens of researchers have carried out their work in this laboratory, and as a team we have leaded translational and clinical projects through both preclinical studies with experimental models, as well as cohort studies in patients. The laboratory stands out for its extensive national and international collaborations, working closely with other research groups and the biomedical industry.
Our research focuses on identifying new therapeutic targets for cerebroprotection and brain repair, discovering diagnostic, prognostic, and recovery biomarkers in both biological fluids and neuroimaging, and investigating the mechanisms of neuronal and vascular damage. We also work in regenerative medicine and nanomedicine fields, with strong expertise in preclinical models of stroke, cerebral amyloidosis, and Alzheimer’s disease. More specifically, our main research lines are:
PMID: 31731108 Journal: EPILEPSY & BEHAVIOR Year: 2020 Reference: Epilepsy Behav. 2020 Jan;102:106657. doi: 10.1016/j.yebeh.2019.106657. Epub 2019 Nov 12. Impact factor: 2.508 Publication type: Paper in international publication Authors: Quintana, Manuel, Abraira, Laura, Santamarina, Estevo, Salas-Puig, Xavier, Toledo, Manuel, Guzman, Lorena, Fonseca, Elena et al. DOI: 10.1016/j.yebeh.2019.106657
PMID: 32078495 Journal: STROKE Year: 2020 Reference: Stroke. 2020 Apr;51(4):1313-1316. doi: 10.1161/STROKEAHA.119.028787. Epub 2020 Feb 14. Impact factor: 7.19 Publication type: Paper in international publication Authors: Garcia-Tornel, Alvaro, Rubiera, Marta, Requena, Manuel, Muchada, Marian, Pagola, Jorge, Rodriguez-Luna, David, Deck, Matias, Juega, Jesus, Rodriguez-Villatoro, Noelia, Boned, Sandra et al. DOI: 10.1161/STROKEAHA.119.028787
PMID: 32057060 Journal: Nanoscale Year: 2020 Reference: Nanoscale. 2020 Feb 27;12(8):4988-5002. doi: 10.1039/c9nr10620k. Impact factor: 6.895 Publication type: Paper in international publication Authors: Llop, Jordi, Zhang, Yajie, Garcia-Gabilondo, Miguel, Grayston, Alba, Feiner, Irene V J, Anton-Sales, Irene, Loiola, Rodrigo A, Garcia-Dorado, David, Gosselet, Fabien, Rosell, Anna et al. DOI: 10.1039/c9nr10620k
PMID: 31869590 Journal: JOURNAL OF THE NEUROLOGICAL SCIENCES Year: 2020 Reference: J Neurol Sci. 2020 Feb 15;409:116635. doi: 10.1016/j.jns.2019.116635. Epub 2019 Dec 14. Impact factor: 3.115 Publication type: Paper in international publication Authors: Jimenez-Balado, Joan, Riba-Llena, Iolanda, Pizarro, Jesus, Palasi, Antoni, Penalba, Anna, Ramirez, Clara, Maisterra, Olga, Espinel, Eugenia, Ramos, Natalia, Pujadas, Francesc et al. DOI: 10.1016/j.jns.2019.116635
For three days, the III Stroke Congress of the national RICORS-ICTUS network and a symposium focused on cerebral haemorrhage were held.
The TOUCH MSCA-COFUND doctoral training programme, led by UAB and focusing on the field of mental health, has opened its first call for applications, offering 13 doctoral positions.
The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.
